Get the Stockscreener App
5.88
3.89%
0.22
After Hours:
5.70
-0.18
-3.06%
Bolt Biotherapeutics Inc stock is traded at $5.88, with a volume of 17,573.
It is up +3.89% in the last 24 hours and up +8.49% over the past month.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
See More
Previous Close:
$5.66
Open:
$5.5
24h Volume:
17,573
Relative Volume:
0.53
Market Cap:
$11.29M
Revenue:
$4.17M
Net Income/Loss:
$-50.71M
P/E Ratio:
-0.4364
EPS:
-13.474
Net Cash Flow:
$-51.40M
1W Performance:
+10.94%
1M Performance:
+8.49%
6M Performance:
-0.68%
1Y Performance:
-52.29%
1-Day Range:
$5.50
$5.9599
1-Week Range:
$5.18
$5.9599
52-Week Range:
$4.41
$12.60
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Name
Bolt Biotherapeutics Inc
Sector
Industry
Phone
650-665-9295
Address
900 CHESAPEAKE DRIVE, REDWOOD CITY
Compare BOLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
5.88 | 10.86M | 4.17M | -50.71M | -51.40M | -13.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Resumed | H.C. Wainwright | Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-02-21 | Initiated | Guggenheim | Buy |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Bolt Biotherapeutics Inc Stock (BOLT) Latest News
Is Bolt Biotherapeutics Inc. (6LP0) stock a fit for income portfolios2026 world cup usa national team quarterfinals goalkeepers set piece tactics expert forecast expert opinion - Улправда
Will Bolt Biotherapeutics Inc. (6LP0) stock enhance shareholder value2026 world cup usa national team semifinals defensive leaders set piece tactics knockout prediction breakdown - Улправда
Street Watch: Why Bolt Biotherapeutics Inc. stock could rally in 2025Trade Ideas & Short-Term Trading Alerts - moha.gov.vn
Performance Recap: Will STEM stock test record highs in 2025Earnings Miss & Technical Analysis for Trade Confirmation - moha.gov.vn
Bajaj Electricals Limited Attempts Reversal From Key SupportProtective Put Strategies & Diversify Intelligently to Avoid Big Hits - bollywoodhelpline.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Bloom Dekor Limited (526225) Announces Strategic ShiftMoving Average Crossovers & Free Stop-Loss Planning for Your Portfolio - bollywoodhelpline.com
BOLT SEC FilingsBolt Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Bolt Biotherapeutics (NASDAQ:BOLT) Share Price Passes Below Two Hundred Day Moving Average – What’s Next? - Defense World
Why Bolt Biotherapeutics Inc. stock could rally in 2025Trade Analysis Report & Free Safe Entry Trade Signal Reports - Улправда
Published on: 2025-12-21 07:10:36 - Улправда
Will Bolt Biotherapeutics Inc. stock outperform tech sector in 2025Recession Risk & Fast Gain Stock Tips - ulpravda.ru
What analyst consensus says on Bolt Biotherapeutics Inc. stockDay Trade & High Accuracy Buy Signal Tips - Улправда
Published on: 2025-12-20 08:01:52 - Улправда
Will Bolt Biotherapeutics Inc. stock rally after Fed decisionsDollar Strength & Verified High Yield Trade Plans - Улправда
Will Bolt Biotherapeutics Inc. stock beat EPS estimatesGDP Growth & Risk Controlled Swing Alerts - DonanımHaber
Will Bolt Biotherapeutics Inc. stock reach all time highs in 2025Market Performance Summary & Weekly High Momentum Picks - DonanımHaber
Shorts Report: Is Bolt Biotherapeutics Inc. stock vulnerable to regulatory risksMarket Risk Report & Daily Oversold Stock Bounce Ideas - DonanımHaber
Layoff Tracker: Voyager Loses 30 Employees After Novartis Prunes Deal - BioSpace
Is Bolt Biotherapeutics Inc. (6LP0) stock undervalued at current price2025 Pullback Review & Entry and Exit Point Strategies - Улправда
Published on: 2025-12-19 09:21:25 - Улправда
Aug Intraday: Is Bolt Biotherapeutics Inc. stock trading at a premium valuation2025 Risk Factors & Precise Trade Entry Recommendations - Улправда
Investor Mood: Why Bolt Biotherapeutics Inc. stock could rally in 2025Insider Buying & Expert Approved Trade Ideas - Улправда
Is Bolt Biotherapeutics Inc. stock trading at a premium valuationBreakout Watch & Long-Term Growth Plans - Улправда
Cash per share of Bolt Biotherapeutics, Inc. – BER:6LP0 - TradingView — Track All Markets
Bolt Biotherapeutics (BOLT) director files insider option changes on Form 4 - Stock Titan
Bolt Biotherapeutics (BOLT) reports director stock option replacement details - Stock Titan
Bolt Biotherapeutics (BOLT) details director stock option grants, repricing - Stock Titan
Bolt Biotherapeutics (BOLT) director reports option cancellations and new $5.44 grants - Stock Titan
Bolt Biotherapeutics (BOLT) executive swaps options for lower strike - Stock Titan
Bolt Biotherapeutics (BOLT) COO swaps options for lower strike price - Stock Titan
Financial Review: Acumen Pharmaceuticals (NASDAQ:ABOS) versus Bolt Biotherapeutics (NASDAQ:BOLT) - Defense World
What drives Bolt Biotherapeutics Inc stock priceMACD Histogram Signals & Outstanding Profit Strategies - earlytimes.in
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory - Finviz
What technical signals suggest for Bolt Biotherapeutics Inc. stockTrade Entry Report & Free Verified High Yield Trade Plans - Newser
Will Bolt Biotherapeutics Inc. stock continue dividend increasesWeekly Gains Report & Accurate Entry/Exit Alerts - Newser
Bolt Biotherapeutics2025 Funding Rounds & List of Investors - Tracxn
Revenue per share of Bolt Biotherapeutics, Inc. – MUN:6LP0 - TradingView
Risk Check: Will Bolt Biotherapeutics Inc. stock outperform tech sector in 2025IPO Watch & Safe Swing Trade Setup Alerts - BỘ NỘI VỤ
Risk Recap: Why Bolt Biotherapeutics Inc. stock could rally in 2025July 2025 Momentum & Weekly Watchlist for Consistent Profits - moha.gov.vn
Bolt Biotherapeutics (BOLT) Stock Forecast and Price Target 2025 - MarketBeat
Triple Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Emerging Therapies, Reveals DelveInsight - The Globe and Mail
What analysts say about Bolt Biotherapeutics Inc stockHigh Frequency Trading Trends & Low Risk Trading Plans - earlytimes.in
Bolt Biotherapeutics (NASDAQ:BOLT) Cut to “Hold” at Zacks Research - Defense World
Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy? - MSN
What is the fair value estimate for Bolt Biotherapeutics Inc. (6LP0) stock in 20252025 Biggest Moves & Weekly Watchlist for Hot Stocks - newser.com
How higher bond yields impact Bolt Biotherapeutics Inc. (6LP0) stock2025 Investor Takeaways & Risk Managed Trade Strategies - newser.com
How big funds are accumulating Bolt Biotherapeutics Inc. (6LP0) stock - newser.com
Will Bolt Biotherapeutics Inc. (6LP0) stock beat Nasdaq index returns2025 Market Outlook & Reliable Breakout Forecasts - newser.com
Will Bolt Biotherapeutics Inc. (6LP0) stock keep high P E multiples2025 Analyst Calls & Weekly Top Gainers Alerts - newser.com
Can Bolt Biotherapeutics Inc. (6LP0) stock attract analyst upgrades2025 Key Lessons & High Accuracy Investment Signals - newser.com
Bolt Biotherapeutics Inc Stock (BOLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):